MedTrace Logo

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine

NCT05019248 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2021-08-24

No results posted yet for this study

Summary

The primary objective of this study is to characterize the antibody response to seasonal influenza vaccine, in patients with active RRMS, treated with cladribine, compared to control individuals with basic immunomodulatory treatment. Serum antibody titers against the respective pathogen will be assessed prior to and 6 to 8 months following vaccination.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting
  • Vaccine Response Impaired

Interventions

BIOLOGICAL

Most recent vaccine to seasonal influenza

Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).

Sponsors & Collaborators

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Principal Investigators

  • Sven G Meuth, MD, PhD · Heinrich-Heine-University Duesseldorf, Germany

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-12-31
Completion
2022-04-30
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05019248 on ClinicalTrials.gov